VA-REGULA
16.11.2023 09:01:35 CET | Business Wire | Press release
When investigating digital nomads' journey as new clients, Regula compiled a list of the ten most common activities in various locations spanning the United States, United Kingdom, Germany, Spain, United Arab Emirates, and Mexico. They then called upon respondents to pinpoint the activities causing the utmost distress. Through this approach, the survey brought to light a comparative ranking of countries where businesses encounter difficulties in accommodating users who possess foreign identity documents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116009610/en/
Regula conducted a survey in which they identified the ten most common activities for digital nomads in various locations, encompassing the United States, United Kingdom, Germany, Spain, United Arab Emirates, and Mexico. They asked respondents to highlight the activities causing the utmost distress. This revealed a list of countries where businesses struggle to accommodate users with foreign passports. (Graphic: Business Wire)
Interestingly, nomads are expressing the most frustration when interacting with organizations offering services in the United States. This revelation comes as a surprise, given that the United States was the most frequented destination for the digital nomad community in 2022.
The most painful verification processes for nomads in the USA are linked to specific stages: crossing the border (21 percent of respondents), checking into a hotel (19 percent), renting accommodations (19 percent), activating a new mobile phone or SIM card (17 percent), and securing a rental car (14 percent).
In the second spot, the United Arab Emirates presents its share of hurdles, particularly in the areas of applying for a visa, navigating the intricacies of medical insurance, and procuring age-restricted products.
On the other end of the spectrum, standing out as a prime example of efficiency for foreigners, is Germany. It boasts a majority of seamless verification processes during critical steps, including applying for a visa, boarding a flight, checking into a hotel, activating a new mobile phone or SIM card, opening a bank account, and completing medical insurance paperwork.
It also needs to be highlighted that identity verification use cases vary depending on the country, shaped by the specific nuances of local migration laws. For instance, digital nomads in the UAE and US tend to apply for work permits more frequently than their counterparts elsewhere.
Race against time
Just imagine the bureaucratic labyrinth of numerous registrations, verifications, and account openings with essential organizations in a new location that must be navigated by nomads within just a few weeks or a month.
The most prevalent issue associated with the verification process, cited by 19 percent of the survey's respondents, revolves around document validity periods. Some identification documents come with expiration dates, and for a digital nomad who is far from their home country, renewing these documents on time can pose significant challenges.
The challenge of providing proof of residency is cited by another 19 percent of respondents. Digital nomads often lack a fixed residential address, making it hard to furnish traditional proof-of-residency documents like utility bills or rental agreements.
Linked to the previous point, 18 percent of respondents highlighted the challenge of frequently changing locations. Constant travel and shifts in location can result in inconsistencies in the information provided during ID verification, potentially causing delays or rejections. Lastly, trust and credibility are a top concern for another 18 percent of nomads. They may encounter skepticism or a lack of trust from institutions due to the unconventional nature of their lifestyle and work arrangements.
“Verification poses a daunting task for digital nomads as each country and business enforces its unique rules, often lacking streamlined processes for foreign document verification. In the era of global mobility, businesses and nations cannot ignore this new breed of customers and need to carefully review their users’ journeys to elevate the standards of identity verification processes, making them both simple and secure,”—said Henry Patishman, Executive Vice President of Identity Verification Solutions at Regula.
*The research was initiated by Regula and conducted by Sapio Research in September 2023 using an online survey of digital nomads and Fraud Prevention decision makers across the Software/Tech, Financial and Banking Services, Technology, Telecoms, Travel and Hospitality sectors, and others. The respondent geography included the US, UK, Germany, Spain, UAE, and Mexico.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116009610/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
